5个与猪产仔数相关基因的效应分析

为了比较不同基因对猪产仔数效应大小,在相同的大白 （158头）、长白 （224头）猪群中采用PCR-RFLP法进行了ESR、FSHβ、PRL、PRLR、NCOA1 5种与产仔数相关基因的基因型频率检测及不同基因型的总产仔数和产活仔数效应分析,结果表明,对相同母猪群产仔数影响效应最大的是PRLR和NCOA1基因,AA型比BB型母猪总产仔数高2.28~3.33头（P<0.01）,产活仔数高1.57~3.30头（P<0.01）,其次为ESR和FSHβ基因,BB型比AA型母猪总产仔数高0.55~1.18头（P<0.05,长白例外）,产活仔数高0.37~1.20头（P<0.05）。PRL基因对产仔数效应不显著。     

啮齿动物胎仔数与生活史变量的关系

胎仔数是影响哺乳动物繁殖率的基本参数 ,与动物的生活史变量密切相关。胎仔数及其相关的生活史变量 ,包括后代的质量、幼体的生存、母体的体重及母体的生存等 ,共同影响繁殖适合度。简述了胎仔数与生活史变量关系的研究方法及研究对象的选择 ,着重介绍了胎仔数与幼体和母体生活史变量的关系 :胎仔数与后代的质量呈负相关 ,后代的质量又决定了幼体的生存 ;胎仔数与母体体重相关不显著 ,而且可能对母体的生存产生负面影响。有关胎仔数与其生活史变量的关系还有待于进一步的探索 ,更多先进技术手段与方法的交叉运用将补充和完善胎仔数研究的内容     

Association of BF,RBP4, and ESR2 Genotypes with Litter Size in an Autochthonous Pig Population

The aim of the present study was to determine any potential association of the BF, RBP4, and ESR2 genes with reproduction traits in an autochthonous Greek pig population. The PCR-RFLP methodology was implemented for genotyping purposes of the examined genes. No deviation from the Hardy-Weinberg equilibrium was observed for the examined loci, while the B allele noted to be the more frequent in all analyzed genes. In addition, sows with the AA genotype of BF gene found to produce significantly lower numbers of the total born piglets (TNB) and number of piglets born alive (TNA), while the respective BB genotype significantly exceeded in TNB and NBA traits compared to the other two genotypes (P?Abbreviations: TNB: Total number of born piglets; NBA: Number of piglets born alive     

猪雌激素受体（ESR）基因对产仔数性状的影响

猪产仔数是重要的经济性状,产仔数的提高将会大大地增加商品肉猪的产量,给现代养猪生产带来巨大的经济效益。ＥＳＲ基因是影响猪产仔数的主效基因,而且与猪的生长发育性状及酮体性状之间不存在负的基因多效性影响。采用ＰＣＲ－ＲＦＬＰｓ的方法,通过对５个不同品种的、特别是我国地方品种的２６２头母猪进行了基因多态性分析,研究表明ＥＳＲ基因在这种种群对产仔数均有极显著影响,ＥＳＲ位点ＢＢ基因型母猪平均比ＡＡ基因型母     

中外六个猪种FUT1基因多态性研究

目的对6个中外猪种共245头猪的FUT1基因进行了研究。方法采用PCR-RFLP技术。结果与结论Hin6I位点上,大白猪、长白猪、杜洛克猪3个外来猪种均存在多态,且以敏感型（GG型和AG型）居多;山西黑猪、太原花猪、马身猪3个本地猪种的所有检测样品都表现为GG型。     

Functional Hypermethylation of ALDH1L1 , PLCL2 , and PPP2R3A in Colon Cancer

DNA hypermethylation and mutations are key mechanisms for the downregulation of tumor suppressor genes. NotI-microarrays allowed us to detect hypermethylation and/or deletions in 180 NotI sites associated with 188 genes of human chromosome 3, in 24 paired (tumor/normal) colon samples. The most frequent aberrations (in more than 20% of tumor samples) were detected in the promoter regions of 20 genes. Expression and promoter methylation of these genes were analyzed using the data for paired colon samples from The Cancer Genome Atlas project. Three genes—ALDH1L1, PLCL2, and PPP2R3A—revealed a more than two-fold average decrease in expression and a negative correlation between mRNA level and promoter hypermethylation. The expression of these three genes was then evaluated in 30 paired colon samples by quantitative PCR. Frequent (in more than 60% of cases) and significant (5–9-fold on average) mRNA level decrease was found for each of the genes in the tumor samples. The results indicate a suppressor role of the ALDH1L1, PLCL2, and PPP2R3A genes in colon cancer, as well as functional significance of hypermethylation in the downregulation of these genes.     

Maternal Aggression and Litter Size in the Female House Mouse

It has been commonly argued that, in house mice, female post-partum fighting against a male intruder functions to protect the offspring from infanticide. The aim of this study was to test the hypothesis that maternal aggression is actually related to pup defence and, specifically, according to parental investment theory, that its intensity should increase with litter size. 60 nulliparous albino female mice were mated and randomly assigned to four experimental groups in which litters were culled at birth to 0, 4, 8, or 12 pups, respectively. On day 8 after delivery all females were tested for maternal aggression against a stranger adult male conspecific (5-min exposure). No aggression occurred in the group in which all pups had been removed. In the other groups, the proportion of females displaying overt aggression increased with litter size. Several scores of female agonistic behaviour (proportion of females displaying overt aggression, total attacking time, frequency of tail rattling) were significantly higher for the females rearing 8 and 12 pups than for the females rearing 4 pups. Aggressive behaviour of females rearing 12 pups was not significantly higher than that of females rearing 8 pups. No male committed infanticide. These results support the hypothesis that rodent maternal aggression is strictly related to offspring defence and are consistent with the theoretical prediction that, the costs of the defence being equal and the gain in fitness increasing with litter size, the intensity of maternal defence of the young should increase with their number.     

母猪生殖器官大小和产仔数的分子遗传基础

采用单核苷酸多态分析技术（SNP）分析母猪3个生殖激素受体基因（ESR、PRLR和FSHR）的变异,屠宰103头母猪并测定其生殖器官大小;统计母猪的产仔数;利用SAS或SPSS分析软件分析基因变异与母猪的生殖器官大小,产仔数多少的连锁关系,以探讨母猪生殖器官大小和产仔数多少的分子遗传基础,结果表明,如母猪携带的基因型为位点,ESR的BB型,位点FSHRB的BB型,位点ESRB的AA型,位点PRLR的AA型,则母猪的生殖器官较大,产仔数也较多;在位点ESRB或位点PRLR中,带有AA基因型母猪不仅产仔数显著地高于AB、BB型,而且生殖器官也显著大于AB、BB型;在位点ESR和FSHRB中,带有BB基因型母猪的生殖器官,产仔数显著高于带有AB或AA型母猪。     

NDRG1对人肠癌细胞失巢凋亡的影响

目的:探讨NDRG1对体外培养的人肠癌细胞系失巣凋亡的影响。方法:采用慢病毒系统将NDRG1表达单元转入人肠癌细胞系SW620、HCT8中,建立相应的过表达稳定细胞系;通过siRNA的方法干扰HCT116和LOVO细胞系中NDRG1的表达,分别在非贴壁培养的情况下培养48小时,采用流式细胞术和TUNEL染色检测细胞的凋亡情况。结果:在贴壁培养条件下,NDRG1过表达并没有显著影响肠癌细胞的生长及增殖,而NDRG1特异性siRNA干扰HCT116细胞中NDRG1的表达后,其凋亡率无明显变化(P0.05)。在悬浮培养条件下,NDRG1过表达的肠癌细胞的失巢凋亡率显著低于正常对照组(P0.05),而用三种不同的siRNA干扰HCT116及LOVO细胞中NDRG1的表达后,其失巢凋亡率均显著高于正常对照组(P0.05)。结论:NDRG1在体外可抑制人肠癌细胞的失巢凋亡。     

MACC1在结肠癌中表达及其临床病理意义

目的：观察MAccl（metastasis．associatedincoloncancer-1）在结肠癌中的表达并分析其与大肠癌临床病理特征的关系。方法：选择我院2001年1月～2011年12月收治的317例接受结肠癌根治术治疗的结肠癌患者为研究对象,通过免疫组织化学技术检测MACCl在结肠癌及癌旁正常结肠组织中的表达,并分析MACCl的表达与结肠癌患者临床病理指标和生存期的相关性。结果：MACCl在结肠癌中的阳性表达率选择高于癌旁正常结肠组织（P〈0．05）。MACCl的表达与肿瘤的大小、临床分期、淋巴结转移、远处转移均显著相关（P〈0．05）,MACCl阳性表达病例的肿瘤体积较MACCl阴性表达病例大,临床分期较MACCl阴性表达病例晚,淋巴结转移和远处转移的发生率较MACCl阴性表达者高,均有统计学意义（P〈0．05）。MACCl阳性表达病例的生存率和生存期均较MACCl阴性表达病例显著降低和缩短（P=0．01）。结论：MACCl的表达上调与结肠癌的发生发展密切相关,可能作为评估结肠癌患者预后的参考指标。     

Elevated Expression of the cdc25A Protein Phosphatase in Colon Cancer

The nuclear protein phosphatase cdc25A has been postulated to be a protooncogene. The total nuclear phosphotyrosyl protein phosphatase (PTP) activity and the expression of cdc25A were compared in normal and cancerous colon epithelial tissue. Nuclei derived from normal mucosal epithelium and tumors were analyzed for phosphotyrosyl protein phosphatase activity using the malachite green assay and a synthetic phosphotyrosyl peptide based on the sequence of cdc2, a known cdc25A phosphotyrosyl protein substrate. Tumorigenesis resulted in elevated nuclear PTP activity (343.0 ± 37.0% of normal epithelial PTP activity) in 52% (29 of 56) of colon tumors. In all cases elevated nuclear PTP activity correlated with an increase in the expression of cdc25A. The changes in PTP activity observed were not due to any increase in the rate of growth of the colonic mucosa as no corresponding changes occurred with PTP activity under conditions of rapid mucosal growth.     

Metformin: A Potential Therapeutic Agent for Recurrent Colon Cancer

Accumulating evidence suggests that metformin, a biguanide class of anti-diabetic drugs, possesses anti-cancer properties. However, most of the studies to evaluate therapeutic efficacy of metformin have been on primary cancer. No information is available whether metformin could be effectively used for recurrent cancer, specifically colorectal cancer (CRC) that affects up to 50% of patients treated by conventional chemotherapies. Although the reasons for recurrence are not fully understood, it is thought to be due to re-emergence of chemotherapy-resistant cancer stem/stem-like cells (CSCs/CSLCs). Therefore, development of non-toxic treatment strategies targeting CSCs would be of significant therapeutic benefit.In the current investigation, we have examined the effectiveness of metformin, in combination with 5-fluorouracil and oxaliplatin (FuOx), the mainstay of colon cancer therapeutics, on survival of chemo-resistant colon cancer cells that are highly enriched in CSCs/CSLCs. Our data show that metformin acts synergistically with FuOx to (a) induce cell death in chemo resistant (CR) HT-29 and HCT-116 colon cancer cells, (b) inhibit colonospheres formation and (c) enhance colonospheres disintegration. In vitro cell culture studies have further demonstrated that the combinatorial treatment inhibits migration of CR colon cancer cells. These changes were associated with increased miRNA 145 and reduction in miRNA 21. Wnt/β-catenin signaling pathway was also down-regulated indicating its pivotal role in regulating the growth of CR colon cancer cells. Data from SCID mice xenograft model of CR HCT-116 and CR HT-29 cells show that the combination of metformin and FuOX is highly effective in inhibiting the growth of colon tumors as evidenced by ∼50% inhibition in growth following 5 weeks of combination treatment, when compared with the vehicle treated controls. Our current data suggest that metformin together with conventional chemotherapy could be an effective treatment regimen for recurring colorectal cancer (CRC).     

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

In carcinogenesis, the "field defect" is recognized clinically because of the high propensity of survivors of certain cancers to develop other malignancies of the same tissue type, often in a nearby location. Such field defects have been indicated in colon cancer. The molecular abnormalities that are responsible for a field defect in the colon should be detectable at high frequency in the histologically normal tissue surrounding a colonic adenocarcinoma or surrounding an adenoma with advanced neoplasia (well on the way to a colon cancer), but at low frequency in the colonic mucosa from patients without colonic neoplasia.Using immunohistochemistry, entire crypts within 10 cm on each side of colonic adenocarcinomas or advanced colonic neoplasias were found to be frequently reduced or absent in expression for two DNA repair proteins, Pms2 and/or ERCC1. Pms2 is a dual role protein, active in DNA mismatch repair as well as needed in apoptosis of cells with excess DNA damage. ERCC1 is active in DNA nucleotide excision repair. The reduced or absent expression of both ERCC1 and Pms2 would create cells with both increased ability to survive (apoptosis resistance) and increased level of mutability. The reduced or absent expression of both ERCC1 and Pms2 is likely an early step in progression to colon cancer.DNA repair gene Ku86 (active in DNA non-homologous end joining) and Cytochrome c Oxidase Subunit I (involved in apoptosis) had each been reported to be decreased in expression in mucosal areas close to colon cancers. However, immunohistochemical evaluation of their levels of expression showed only low to modest frequencies of crypts to be deficient in their expression in a field defect surrounding colon cancer or surrounding advanced colonic neoplasia.We show, here, our method of evaluation of crypts for expression of ERCC1, Pms2, Ku86 and CcOI. We show that frequency of entire crypts deficient for Pms2 and ERCC1 is often as great as 70% to 95% in 20 cm long areas surrounding a colonic neoplasia, while frequency of crypts deficient in Ku86 has a median value of 2% and frequency of crypts deficient in CcOI has a median value of 16% in these areas. The entire colon is 150 cm long (about 5 feet) and has about 10 million crypts in its mucosal layer. The defect in Pms2 and ERCC1 surrounding a colon cancer thus may include 1 million crypts. It is from a defective crypt that colon cancer arises.